Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
INNOVAX® ND Vaccine
EN
HVT/NDV-F
No
-
Person:Dr Leonardo Bruno Ribeiro CostaPresident of Biosafety Intern Comission, CIBioAv. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala "E", Moinho Velho.Cotia, São Paulo
06714-050, BrazilPhone: 55 (11) 4613-4000 / 4613-4006,Fax: 55 (11) 4613-4000 / 4613-4006,Email: sonia.bognar@intervet.com,Website:Related OrganizationIntervet do Brasil Veterinária Ltda (INTERVET)Private sector (business and industry)Av. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala "E", Moinho Velho.Cotia, São Paulo
06714-050, BrazilPhone: 55 (11) 4613-4000 / 4613-4006,Fax: 55 (11) 4613-4000 / 4613-4006,Email: sonia.bognar@intervet.com,Website:
Innovax®-ND, a recombinant vaccine that helps aid in the protection of Newcastle and Marek’s diseases in chickens. Innovax-ND utilizes the herpesvirus of turkey (HVT) to carry Newcastle disease (ND) antigens, which induce immunity against ND. HVT also protects chickens against Marek’s disease, which is caused by a herpesvirus and results in tumors, high mortality and immunosuppression.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-48969-9 Organism Gallid alphaherpesvirus 2Viruses
PB1 strain: non-virulent , non pathogenic strain of the HTV virus, which is used as a vaccine for over two decades.
EN
pNDVO4
EN
- Other (Homologous Recombination)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-105090-4 Fusion protein gene | Avian orthoavulavirus 1 (Newcastle disease virus, NDV)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
The INNOVAX® ND Vaccine is a recombinant HVT strain that contains a gene that codes for the fusion protein (F-protein) of the Newcastle Disease virus, directed by promoter derived from the Rous sarcoma virus long terminal repeat sequence (LTR).
The gene was integrated into the host genome through homologous recombination as follows:
1. The protein F coding sequence was obtained through cDNA synthesis of genomic NDV, clone 30, RNA that was harvested and purified from infected embryonated eggs.
2. The F-protein coding cDNA was isolated and cloned into the HVT recombination vector pVECO4, which also contains the Rous sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.
3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
4. Selection of the recombinant virus was conducted by immunofluorescence, to detect F protein expression. The resulting strain was named HVT/NDV-F. Sequences of plasmids or markers were not detected in the recombinant virus.
EN
The gene was integrated into the host genome through homologous recombination as follows:
1. The protein F coding sequence was obtained through cDNA synthesis of genomic NDV, clone 30, RNA that was harvested and purified from infected embryonated eggs.
2. The F-protein coding cDNA was isolated and cloned into the HVT recombination vector pVECO4, which also contains the Rous sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.
3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
4. Selection of the recombinant virus was conducted by immunofluorescence, to detect F protein expression. The resulting strain was named HVT/NDV-F. Sequences of plasmids or markers were not detected in the recombinant virus.
EN
- Vaccine
EN
With the use of the Innovax ND vaccine, immunity against Newcastle Disease starts at two weeks of age and lasts for at least of 60 weeks after one single dose of the vaccine. For Marek’s Disease, immunity starts at the fifth day of age and the vaccine lastes for the whole period of risk.
The vaccine is administered to chicken embryonic eggs at 18 days of incubation through the in ovo route, or to one day chicks through subcutaneous injections.
EN
The vaccine is administered to chicken embryonic eggs at 18 days of incubation through the in ovo route, or to one day chicks through subcutaneous injections.
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | LMO identification | 4 | |
| Risk Assessment generated by a regulatory process | Living modified organism(s) | 4 | |
